BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM. Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma. Am J Clin Pathol 2016;145:449-58. [PMID: 27149024 DOI: 10.1093/ajcp/aqw030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Hinchcliff E, Rumpf J, Ratan R, Fleming ND, Jazaeri A, Fellman B, Meyer L, Soliman P. Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma. Gynecol Oncol 2022;167:490-5. [PMID: 36270831 DOI: 10.1016/j.ygyno.2022.09.024] [Reference Citation Analysis]
2 Croce S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, Treilleux I, Neuville A, Arnould L, Just PA, Belda MALF, Averous G, Leroux A, Mery E, Loussouarn D, Weinbreck N, Le Guellec S, Mishellany F, Morice P, Guyon F, Genestie C. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group. Gynecol Oncol 2022:S0090-8258(22)00515-7. [PMID: 36114030 DOI: 10.1016/j.ygyno.2022.07.031] [Reference Citation Analysis]
3 Ronsini C, Foresta A, Giudice M, Reino A, La Verde M, Corte LD, Bifulco G, Franciscis PD, Cianci S, Capozzi VA. Is Adnexectomy Mandatory at the Time of Hysterectomy for Uterine Sarcomas? A Systematic Review and Meta-Analysis. Medicina 2022;58:1140. [DOI: 10.3390/medicina58091140] [Reference Citation Analysis]
4 Borella F, Cosma S, Ferraioli D, Ray-Coquard I, Chopin N, Meeus P, Cockenpot V, Valabrerga G, Scotto G, Turinetto M, Biglia N, Fuso L, Mariani L, Franchi D, Vidal Urbinati AM, Pino I, Bertschy G, Preti M, Benedetto C, Castellano I, Cassoni P, Bertero L. Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers. Ann Surg Oncol 2022. [PMID: 35976464 DOI: 10.1245/s10434-022-12353-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Huss A, Klar M, Hasanov MF, Juhasz-Böss I, Bossart M. Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis. Arch Gynecol Obstet 2022. [PMID: 35780401 DOI: 10.1007/s00404-022-06515-2] [Reference Citation Analysis]
6 Maccaroni E, Lunerti V, Agostinelli V, Giampieri R, Zepponi L, Pagliacci A, Berardi R. New Insights into Hormonal Therapies in Uterine Sarcomas. Cancers 2022;14:921. [DOI: 10.3390/cancers14040921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sia TY, Huang Y, Gockley A, Melamed A, Khoury-Collado F, St Clair C, Hou JY, Tergas AI, Hershman DL, Wright JD. Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma. Gynecol Oncol 2021;161:734-40. [PMID: 33810881 DOI: 10.1016/j.ygyno.2021.03.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Wei J, Purdy J. Uterine Mesenchymal Neoplasia. Practical Gynecologic Pathology 2021. [DOI: 10.1007/978-3-030-68608-6_6] [Reference Citation Analysis]
9 Ferrandina G, Aristei C, Biondetti PR, Cananzi FCM, Casali P, Ciccarone F, Colombo N, Comandone A, Corvo' R, De Iaco P, Dei Tos AP, Donato V, Fiore M, Franchi, Gadducci A, Gronchi A, Guerriero S, Infante A, Odicino F, Pirronti T, Quagliuolo V, Sanfilippo R, Testa AC, Zannoni GF, Scambia G, Lorusso D. Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). Eur J Cancer 2020;139:149-68. [PMID: 32992154 DOI: 10.1016/j.ejca.2020.08.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
10 Yorgancı A, Meydanlı MM, Kadıoğlu N, Taşkın S, Kayıkçıoğlu F, Altın D, Atasoy L, Haberal AN, Kınay T, Akgül MA, Tapısız ÖL, Evliyaoğlu Ö, Tekin ÖM, Fırat Ortaç U, Ayhan A. Incidence and outcome of occult uterine sarcoma: A multi-centre study of 18604 operations performed for presumed uterine leiomyoma. J Gynecol Obstet Hum Reprod 2020;49:101631. [PMID: 31499285 DOI: 10.1016/j.jogoh.2019.101631] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
11 Zang Y, Dong M, Zhang K, Gao C, Guo F, Wang Y, Xue F. Hormonal therapy in uterine sarcomas. Cancer Med 2019;8:1339-49. [PMID: 30897294 DOI: 10.1002/cam4.2044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
12 Howitt BE, Nucci MR. Uterine Mesenchymal Lesions. Gynecologic and Obstetric Pathology, Volume 2 2019. [DOI: 10.1007/978-981-13-3019-3_1] [Reference Citation Analysis]
13 Díaz-montes TP, El-sharkawy F, Lynam S, Harper A, Sittig M, Macdonald R, Gushchin V, Sardi A. Efficacy of Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Treatment of Recurrent Uterine Sarcoma: . International Journal of Gynecological Cancer 2018;28:1130-7. [DOI: 10.1097/igc.0000000000001289] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
14 Song KJ, Yu XN, Lv T, Chen YL, Diao YC, Liu SL, Wang YK, Yao Q. Expression and prognostic value of lactate dehydrogenase-A and -D subunits in human uterine myoma and uterine sarcoma. Medicine (Baltimore) 2018;97:e0268. [PMID: 29620641 DOI: 10.1097/MD.0000000000010268] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
15 Croce S, Ducoulombier A, Ribeiro A, Lesluyes T, Noel JC, Amant F, Guillou L, Stoeckle E, Devouassoux-Shisheboran M, Penel N, Floquet A, Arnould L, Guyon F, Mishellany F, Chakiba C, Cuppens T, Zikan M, Leroux A, Frouin E, Farre I, Genestie C, Valo I, MacGrogan G, Chibon F. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. Mod Pathol 2018;31:816-28. [PMID: 29327710 DOI: 10.1038/modpathol.2017.185] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
16 Zhang Q, Kanis MJ, Ubago J, Liu D, Scholtens DM, Strohl AE, Lurain JR, Shahabi S, Kong B, Wei JJ. The selected biomarker analysis in 5 types of uterine smooth muscle tumors. Hum Pathol 2018;76:17-27. [PMID: 29258902 DOI: 10.1016/j.humpath.2017.12.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
17 Desar IME, Ottevanger PB, Benson C, van der Graaf WTA. Systemic treatment in adult uterine sarcomas. Crit Rev Oncol Hematol. 2018;122:10-20. [PMID: 29458779 DOI: 10.1016/j.critrevonc.2017.12.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
18 Sardi A, Sipok A, Baratti D, Deraco M, Sugarbaker P, Salti G, Yonemura Y, Sammartino P, Glehen O, Bakrin N, Díaz-Montes TP, Gushchin V. Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2017;43:2170-7. [PMID: 28967566 DOI: 10.1016/j.ejso.2017.08.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
19 Davidson B, Hellesylt E, Holth A, Danielsen HE, Skeie-jensen T, Katz B. Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma. Virchows Arch 2017;471:355-62. [DOI: 10.1007/s00428-017-2172-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Davidson B, Micci F. Molecular characteristics of uterine sarcomas. Expert Rev Mol Diagn 2017;17:515-22. [PMID: 28335657 DOI: 10.1080/14737159.2017.1311790] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
21 Chow KL, Tse KY, Cheung CL, Wong KW, Cheung AN, Wong RW, Chan AN, Yuen NW, Ngan HY, Ip PP. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study. Histopathology 2017;70:746-55. [PMID: 27864989 DOI: 10.1111/his.13124] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
22 Pellanda AF, De Bari B, Deniaud-Alexandre E, Krengli M, Van Houtte P, Richetti A, Villà S, Goldberg H, Szutowicz-Zielińska E, Bolla M, Rutten H, Van Eijkeren M, Poortmans P, Henke G, Anacak Y, Chan S, Landmann C, Kirkove C, Scandolaro L, Bernier J, Mirimanoff RO, Ozsahin M. Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study. Chin J Cancer Res 2017;29:521-32. [PMID: 29353974 DOI: 10.21147/j.issn.1000-9604.2017.06.06] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]